Joseph A. Odin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Joseph A. Odin has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
Livia Casciola-Rosen
Department of Medicine, The Mount Sinai School of Medicine, New York, New York, USA2Center for Basic Research in Digestive Disease, Division of Gastroenterology and Hepatology, Mayo Medical School, Clinic and Foundation, Rochester, Minnesota, USA3Department of Dermatology,4Department of Medicine, and5Department of Cell Biology and Anatomy, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
2 shared publicationsAntony Rosen
Department of Medicine, The Mount Sinai School of Medicine, New York, New York, USA2Center for Basic Research in Digestive Disease, Division of Gastroenterology and Hepatology, Mayo Medical School, Clinic and Foundation, Rochester, Minnesota, USA3Department of Dermatology,4Department of Medicine, and5Department of Cell Biology and Anatomy, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
1 shared publication- Antony Rosen
Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
1 shared publication - James A. Mahoney
Department of Medicine, The Johns Hopkins University School of Medicine, 720 Rutland Avenue, Baltimore, MD 21205, U.S.A.
1 shared publication Nicholas F. LaRusso
Department of Medicine, The Mount Sinai School of Medicine, New York, New York, USA2Center for Basic Research in Digestive Disease, Division of Gastroenterology and Hepatology, Mayo Medical School, Clinic and Foundation, Rochester, Minnesota, USA3Department of Dermatology,4Department of Medicine, and5Department of Cell Biology and Anatomy, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
1 shared publication- Robert C. Huebert
Division of Gastroenterology and Hepatology, Mayo Clinic, 200 1st Street SW, Rochester, MN 55905, USA
1 shared publication
Latest Publications
- Open Access
- 15 July 2001
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 108 (2) , 223-232
Bcl-2–dependent oxidation of pyruvate dehydrogenase-E2, a primary biliary cirrhosis autoantigen, during apoptosis
The close association between autoantibodies against pyruvate dehydrogenase-E2 (PDC-E2), a ubiquitous mitochondrial protein, and primary biliary cirrhosis (PBC) is unexplained. Many autoantigens are selectively modified during apoptosis, which has focused attention on apoptotic cells as a potential source of “neo-antigens” responsible for activating autoreactive lymphocytes. Since increased apoptosis of bile duct epithelial cells (cholangiocytes) is evident in patients with PBC, we evaluated the effect of apoptosis on PDC-E2. Autoantibody recognition of PDC-E2 by immunofluorescence persisted in apoptotic cholangiocytes and appeared unchanged by immunoblot analysis. PDC-E2 was neither cleaved by caspases nor concentrated into surface blebs in apoptotic cells. In other cell types, autoantibody recognition of PDC-E2, as assessed by immunofluorescence, was abrogated after apoptosis, although expression levels of PDC-E2 appeared unchanged when examined by immunoblot analysis. Both overexpression of Bcl-2 and depletion of glutathione before inducing apoptosis prevented this loss of autoantibody recognition, suggesting that glutathiolation, rather than degradation or loss, of PDC-E2 was responsible for the loss of immunofluorescence signal. We postulate that apoptotic cholangiocytes, unlike other apoptotic cell types, are a potential source of immunogenic PDC-E2 in patients with PBC.
- 15 July 2001
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 108 (2) , 223-232
Open AccessBcl-2–dependent oxidation of pyruvate dehydrogenase-E2, a primary biliary cirrhosis autoantigen, during apoptosis
The close association between autoantibodies against pyruvate dehydrogenase-E2 (PDC-E2), a ubiquitous mitochondrial protein, and primary biliary cirrhosis (PBC) is unexplained. Many autoantigens are selectively modified during apoptosis, which has focused attention on apoptotic cells as a potential source of “neo-antigens” responsible for activating autoreactive lymphocytes. Since increased apoptosis of bile duct epithelial cells (cholangiocytes) is evident in patients with PBC, we evaluated the effect of apoptosis on PDC-E2. Autoantibody recognition of PDC-E2 by immunofluorescence persisted in apoptotic cholangiocytes and appeared unchanged by immunoblot analysis. PDC-E2 was neither cleaved by caspases nor concentrated into surface blebs in apoptotic cells. In other cell types, autoantibody recognition of PDC-E2, as assessed by immunofluorescence, was abrogated after apoptosis, although expression levels of PDC-E2 appeared unchanged when examined by immunoblot analysis. Both overexpression of Bcl-2 and depletion of glutathione before inducing apoptosis prevented this loss of autoantibody recognition, suggesting that glutathiolation, rather than degradation or loss, of PDC-E2 was responsible for the loss of immunofluorescence signal. We postulate that apoptotic cholangiocytes, unlike other apoptotic cell types, are a potential source of immunogenic PDC-E2 in patients with PBC.
- 30 April 2000
- Published by Elsevier in Gastroenterology
- Vol. 118 (4) , A961
Expression cloning of a novel autoantigen and caspase substrate: Human ubiquitin fusion degradation protein-2 (UFD2)
- 30 April 2000
- Published by Elsevier in Gastroenterology
- Vol. 118 (4) , A961
Expression cloning of a novel autoantigen and caspase substrate: Human ubiquitin fusion degradation protein-2 (UFD2)